ABBV-142 to check side effects and changes in disease activity in adults with idiopathic pulmonary fibrosis.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 platform study randomizes adults with centrally confirmed IPF to receive ABBV-142 or matching placebo in Substudy 1. The master protocol design allows multiple treatments or substudies to be added or closed over time under the same framework. The main goals are to measure safety, tolerability, and changes in disease activity using centrally read HRCT and clinical assessments. Eligible participants must have IPF diagnosed within seven years with a usual or probable UIP pattern and meet other inclusion/exclusion criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP.

Exclusion Criteria:

* History of stroke within 6 months prior to screening
* In the opinion of the investigator, other clinically significant pulmonary abnormalities
* History of any malignancy up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix.

Where it's running

• The University of Alabama at Birmingham /ID# 277613
  Birmingham, Alabama, United States Recruiting
• Sec Clinical Research - East - Dothan - Graceland /ID# 278328
  Dothan, Alabama, United States Recruiting
• Clinical Research Specialists - Kissimmee /ID# 279184
  Kissimmee, Florida, United States Recruiting
• Christie Clinic on University /ID# 277871
  Champaign, Illinois, United States Recruiting
• University of Michigan Health System - Ann Arbor /ID# 279994
  Ann Arbor, Michigan, United States Recruiting
• Henry Ford Hospital /ID# 277843
  Detroit, Michigan, United States Recruiting

+7 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New IPF drug ORJ-001 tested in adults with IPF

  A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.

  Recruiting at 2 sites Phase 2 Oorja Bio, Inc. · Doral, Florida and 1 other locations · NCT07869147

• Nalbuphine ER for IPF-related chronic cough

  This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.

  Recruiting at 4 sites Phase 3 Trevi Therapeutics · Wilmington, Delaware and 3 other locations · NCT07868419

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Rentosertib by mouth for people with idiopathic pulmonary fibrosis

  This is a randomized, placebo-controlled test to see if Rentosertib helps adults with idiopathic pulmonary fibrosis when taken as a pill.

  Recruiting at 12 sites Phase 3 InSilico Medicine Hong Kong Limited · Hefei, Anhui and 46 other locations · NCT07687459

• Inhaled nintedanib powder for IPF in adults

  This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.

  Recruiting Phase 2 Mannkind Corporation · Windsor, Ontario · NCT07679893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.